Jacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement

Stock News

Oct 28

Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.

ULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.

This licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1174469961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174469961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174469961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174469961","market":"nz","top_or_hot":-1,"title":"Jacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement","media":"Stock News","content":"<p>Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.</p>\n<p>ULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.</p>\n<p>This licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-28 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.</p>\n<p>ULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.</p>\n<p>This licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"","article_id":"1174469961","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174469961","pubTimestamp":1761648507,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1585":"昨日强势股","02161":"健倍苗苗","01711":"欧化","BK1201":"家庭装饰零售","BK1191":"制药","BK1606":"中医药概念","02633":"雅各臣科研制药"},"translate_title":"雅各臣药业(02633)与健邦医疗(02161)：ULFERTS与ULFERTS(香港)订立2025年许可协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01711":1,"02161":1,"02633":1},"content_text":"Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.\nULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.\nThis licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}